Correlates of Human Papillomavirus Vaccine Coverage
نویسندگان
چکیده
منابع مشابه
Correlates of human papillomavirus vaccine coverage: a state-level analysis.
BACKGROUND We tested the hypothesis that states with higher rates of cancers associated with human papillomavirus (HPV) would have lower HPV vaccine coverage. METHODS We gathered state-level data on HPV-related cancer rates and HPV vaccine initiation coverage for girls and boys, separately, and HPV vaccine follow-through (i.e., receipt of 3 doses among those initiating the series) for girls o...
متن کاملQuadrivalent human papillomavirus vaccine.
The lifetime risk of human papillomavirus (HPV) infection exceeds 50%. HPV infection causes >550,000 cases of cervical and anogenital cancer worldwide annually. Infection also causes precancerous lesions and genital warts. HPV types 16 and 18 cause approximately 70% of HPV-related cancers, and HPV types 6 and 11 cause approximately 90% of cases of genital warts. A quadrivalent vaccine for HPV t...
متن کاملHuman papillomavirus vaccine and pregnancy.
UNLABELLED QUESTION A: patient of mine who recently learned she was 6 weeks pregnant had received the recombinant human papillomavirus (HPV) quadrivalent vaccine at 4 weeks of gestation. She is quite worried about how this will affect her baby. What is known about the safety of the HPV vaccine during pregnancy? ANSWER The HPV vaccine is generally not recommended for use in pregnant women. How...
متن کاملHuman papillomavirus vaccine coverage among female Australian adolescents: success of the school-based approach.
OBJECTIVE To describe quadrivalent human papillomavirus (HPV) vaccination coverage achieved in the HPV vaccination catch-up program for girls aged 12-17 years. DESIGN Analysis of data from the Australian National HPV Vaccination Program Register. PARTICIPANTS Girls aged 12-17 years as at 30 June 2007. MAIN OUTCOME MEASURES HPV vaccine coverage by dose (1, 2 and 3), age and state of reside...
متن کاملHuman papillomavirus (HPV) vaccine coverage achievements in low and middle-income countries 2007–2016
INTRODUCTION Since 2007, HPV vaccine has been available to low and middle income countries (LAMIC) for small-scale 'demonstration projects', or national programmes. We analysed coverage achieved in HPV vaccine demonstration projects and national programmes that had completed at least 6 months of implementation between January 2007-2016. METHODS A mapping exercise identified 45 LAMICs with HPV...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Sexually Transmitted Diseases
سال: 2015
ISSN: 0148-5717
DOI: 10.1097/olq.0000000000000225